Stefan Anker

2 weeks ago | onlinelibrary.wiley.com | Stefan Anker |Michele Robertson |John McMurray |Pardeep S. Jhund

Supporting Information Filename Description ejhf3670-sup-0001-supinfo.docxWord 2007 document , 24.6 KB Appendix S1. Supporting Information. References 1, , , , , , et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Statistical methods for recurrent event analysis in cohort studies of CKD. Clin J Am Soc Nephrol 2017; 12: 2066–2073. https://doi.org/10.2215/CJN.12841216 2, .

2 weeks ago | medscape.com | Ileana L. Piña |Stefan Anker

This transcript has been edited for clarity. Ileana L. Piña, MD, MPH: Hello. I’m Ileana Piña from Jefferson University in Philadelphia. I am the quality chief for the cardiovascular line in the Division of Cardiology. I am thrilled to have my good friend, Dr Stefan Anker, who is a clinical trialist par excellence in Berlin, at Charité Hospital, which by the way puts in more devices than anybody else in Europe. You are presenting the FAIR-HF2 trial. Okay.

2 months ago | jamanetwork.com | Stefan Anker |Campus Virchow Klinikum |Tim Friede |Javed Butler

Visual Abstract. Efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency Figure 1.  Recruitment, Randomization, and Follow-Up in the FAIR-HF2 Trial FAIR-HF2 indicates Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity and Mortality. aThe precise reasons are unknown.

2 months ago | nature.com | Stefan Anker |Javed Butler |Frank Rockhold |Christian Röver |Marius Placzek

AbstractUncertainty remains about the effect of intravenous (IV) iron on outcomes for heart failure (HF) with iron deficiency. Here, we summarize the efficacy and safety of IV iron from six trials (FAIR-HF, CONFIRM-HF, AFFIRM-AHF, IRONMAN, HEART-FID, and FAIR-HF2) including 7,175 patients. In comparison to prior analyses, this meta-analysis adds new data from FAIR-HF2, uses a harmonized and robust Bayesian approach, and includes individual participant data from 5 trials.

Jan 28, 2025 | onlinelibrary.wiley.com | Stefan Anker |Tim Friede |Javed Butler |Baylor Scott

Introduction Iron deficiency (ID) is known to impair mitochondrial energy production and cause adverse cardiac remodelling leading to left ventricular dysfunction.1-4 ID is prevalent in up to 50% of patients with heart failure (HF) and is an independently associated with worse functional status, symptoms, and cardiovascular outcomes irrespective of anaemia.5, 6 The FAIR-HF (Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure) trial was the first major trial of...